Study of Bronchoscopic Thermal Vapor Ablation for COPD and Pulmonary Nodule Ablation Using Lung MRI

What this Trial Is About

Researchers are evaluating the effectiveness of bronchoscopic thermal vapor ablation BTVA in patients with chronic obstructive pulmonary disease COPD and the ablation of pulmonary nodules in lung cancer patients. This observational study uses innovative magnetic resonance imaging MRI techniques to assess lung function and treatment effects after surgery. The study focuses on the use of PREFULMRI to evaluate lung ventilation and perfusion in COPD patients after lung volume reduction surgery and GRASPMRI to analyze hemodynamic parameters following pulmonary nodule ablation. Participants include COPD patients treated with thermal steam ablation and patients with malignant pulmonary nodules who have undergone ablative treatments such as radiofrequency, microwave, or freezing ablation. The study observes these patients from enrollment through follow-up periods lasting up to six months post-surgery for COPD and up to three months post-surgery for pulmonary nodules. MRI scans using the PREFUL and GRASP sequences are performed to monitor lung function and treatment impact. During the study, participants will undergo MRI assessments to measure ventilation, perfusion, and hemodynamic changes in the lungs after their respective treatments. Researchers will closely monitor these lung imaging parameters to evaluate treatment efficacy. The study participation spans from enrollment up to six months for COPD patients and three months for pulmonary nodule patients, with a focus on tracking lung function and safety post-treatment using advanced MRI techniques.

Assessment the Effectiveness of BTVA in COPD and Ablation in Pulmonary Nodules by Pulmonary MRI